OBJECTIVES: To investigate the health technology-related costs of Italian inflammatory bowel disease (IBD) centers dealing with Crohn’s disease (CD). METHODS: Following the hospital standpoint, a questionnaire-supported cost description was performed on a convenience sample of 38 Italian IBD centers participating in the ongoing Survey on Quality Of Life in Crohn’s Patients(SOLE). Consistently with their average useful life, a 5-year straight-line depreciation approach was adopted for calculating the yearly cost for each health technology. Cost description was undertaken either considering all centers as an undifferentiated sample, or stratifying them according to their complexity (number of beds for inward and day-hospital; personnel dedicated to CD patients; number of cross-border CD patients; availability of dedicated rooms for biological drugs administration; feasibility of electronic patient forms). Costs (€2012) were reported as mean (standard deviation, SD). RESULTS: Half of centers (19/38) were public teaching hospitals, whereas 39.5% were regional referral centers for CD (15/38). The study sites were located in Northern (12/38, 31.6%), Central (11/38, 28.9%) and Southern (15/38, 39.5%) Italy, and could be classified as high (32/38, 84.2%), moderate (1/38), mild (3/38), and low (2/38) complexity centers. Endoscopy, capsule endoscopy and ultrasonography were the most widespread health technologies available in 92.1%, 78.9% and 34.2% centers, respectively. Considering the undifferentiated sample, mean yearly cost for health technologies amounts to €23,557.50 (€24,277.90). High complexity centers report the highest mean yearly cost of €25,580.38 (€25,706.92), whereas the lowest mean yearly cost of €5,113 (€0) refers to the unique moderate complexity center. Regardless of site complexity, the cost-driver was endoscopy, which accounts for a percentage of the mean yearly cost that ranges from 36.9% (high complexity) to 97.8% (moderate complexity). CONCLUSIONS: SOLE results show that when Italian IBD centers complexity is taken into account, remarkable differences exist about costs for health technologies for managing CD patients.